SwePub
Sök i LIBRIS databas

  Extended search

onr:"swepub:oai:lup.lub.lu.se:27795074-aa94-4153-a454-2d0f67f614f8"
 

Search: onr:"swepub:oai:lup.lub.lu.se:27795074-aa94-4153-a454-2d0f67f614f8" > Bortezomib, melphal...

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist
  • Morabito, Fortunato (author)

Bortezomib, melphalan, prednisone (VMP) versus melphalan, prednisone, thalidomide (MPT) in elderly newly diagnosed multiple myeloma patients: A retrospective case-matched study

  • Article/chapterEnglish2014

Publisher, publication year, extent ...

  • 2014-02-05
  • Wiley,2014

Numbers

  • LIBRIS-ID:oai:lup.lub.lu.se:27795074-aa94-4153-a454-2d0f67f614f8
  • https://lup.lub.lu.se/record/4559302URI
  • https://doi.org/10.1002/ajh.23641DOI

Supplementary language notes

  • Language:English
  • Summary in:English

Part of subdatabase

Classification

  • Subject category:art swepub-publicationtype
  • Subject category:ref swepub-contenttype

Notes

  • Novel agents in combination with melphalan and prednisone (MP) significantly improved progression-free survival (PFS) and overall survival (OS) in multiple myeloma (MM). Randomized trials comparing MP plus bortezomib (VMP) versus MP plus thalidomide (MPT) are lacking. Nine hundred and fifty-six elderly (>65 years) newly diagnosed MM patients from six European randomized trials were retrospectively analyzed and matched for age, albumin, and beta2-microglobulin at diagnosis, 296 patients were selected from the VMP groups, and 294 from MPT. Complete response rate was 21% in the VMP patients and 13% in the MPT patients (P=0.007). After a median follow-up of 34 months (range, 1-92), VMP significantly prolonged both PFS (median 32.5 vs. 22.9 months, HR 0.65; 95% CI 0.52-0.82; P<0.001) and OS (median 79.7 vs. 45.1 months, HR 0.44; 95% CI 0.32-0.59; P<0.001) in comparison with MPT. The benefit in terms of OS of the VMP group was quite similar among patients with different risk factors defined by sex, ISS, ECOG performance status, or serum creatinine but not among patients 75 years. Multivariate analysis confirmed that VMP was an independent predictor of longer PFS and OS. In a control-case matched analysis, PFS and OS were prolonged in patients who received VMP in comparison with those treated with MPT. Am. J. Hematol. 89:355-362, 2014. (c) 2013 Wiley Periodicals, Inc.

Subject headings and genre

Added entries (persons, corporate bodies, meetings, titles ...)

  • Bringhen, Sara (author)
  • Larocca, Alessandra (author)
  • Wijermans, Pierre (author)
  • Victoria Mateos, Maria (author)
  • Gimsing, Peter (author)
  • Mazzone, Carla (author)
  • Gottardi, Daniela (author)
  • Omede, Paola (author)
  • Zweegman, Sonja (author)
  • Jose Lahuerta, Juan (author)
  • Zambello, Renato (author)
  • Musto, Pellegrino (author)
  • Magarotto, Valeria (author)
  • Schaafsma, Martijn (author)
  • Oriol, Albert (author)
  • Juliusson, GunnarLund University,Lunds universitet,Stamcellscentrum (SCC),Avdelningen för stamcellsforskning,Institutionen för laboratoriemedicin,Medicinska fakulteten,Stem Cell Center,Division of stem cell research,Department of Laboratory Medicine,Faculty of Medicine(Swepub:lu)stem-gju (author)
  • Cerrato, Chiara (author)
  • Catalano, Lucio (author)
  • Gentile, Massimo (author)
  • Isabel Turel, Ana (author)
  • Liberati, Anna Marina (author)
  • Cavalli, Maide (author)
  • Rossi, Davide (author)
  • Passera, Roberto (author)
  • Rosso, Stefano (author)
  • Beksac, Meral (author)
  • Cavo, Michele (author)
  • Waage, Anders (author)
  • San Miguel, Jesus (author)
  • Boccadoro, Mario (author)
  • Sonneveld, Pieter (author)
  • Palumbo, Antonio (author)
  • Offidani, Massimo (author)
  • Stamcellscentrum (SCC)Avdelningen för stamcellsforskning (creator_code:org_t)

Related titles

  • In:American Journal of Hematology: Wiley89:4, s. 355-3620361-8609

Internet link

Find in a library

To the university's database

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view